A 22-Year-Old Stanford Grad Raised $11.6 Million to Build a Wearable That Infers Women's Hormones

For decades, women attempting to understand their hormonal health have been trapped between two flawed extremes. On one side are calendar-based period tracking apps, which rely on assumed 28-day averages and frequently fail the roughly 30 percent of women with irregular cycles. On the other side are clinical blood draws—highly accurate, but offering only a static snapshot of a dynamic, constantly shifting biological system.[2]

The gap between what a woman's body is actually doing and what the medical system can conveniently measure has long been dismissed as an unavoidable reality. But a new wave of wearable technology is attempting to close that gap entirely, shifting the paradigm from reactive symptom management to continuous, real-time physiological insight.[4]

At the forefront of this shift is Clair Health, a startup founded by 22-year-old Stanford University graduates Jenny Duan and Abhinav Agarwal. In June 2026, the company announced it had raised $11.6 million in funding led by Khosla Ventures, alongside a roster of prominent health-focused investors including Anne Wojcicki.[1]

The capital injection will fuel the November 2026 launch of Clair's flagship product: a wrist-worn wearable designed to provide a continuous, noninvasive map of female hormone patterns. Already, the concept has struck a nerve, with more than 25,000 people joining the product's waitlist.[1]

The core innovation behind Clair is not a new method of extracting bodily fluids, but rather a sophisticated application of artificial intelligence. The wearable does not measure hormones directly through blood, saliva, or sweat. Instead, it relies on a concept known as physiological inference.[2][4]

The device utilizes 10 distinct biosensors to capture a continuous stream of external physical data. These inputs include skin temperature, resting heart rate, heart rate variability (HRV), sleep architecture, breathing rate, electrodermal activity, and motion tracking.[2][4]

While these metrics are commonly found in standard fitness trackers, Clair's proprietary machine learning models are trained to read these signals specifically through the lens of endocrinology. By fusing these data points, the algorithms infer the real-time levels of four key reproductive hormones: estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH).[2][4]

"We didn't invent the signals that Clair reads," the founders noted earlier this year. "What was missing was the technology to listen. The sensors sophisticated to capture the subtle changes. The models smart enough to fuse multiple signals into coherent predictions."[2]

The scientific foundation for this approach is gaining traction in peer-reviewed literature. Recent research published in the journal Computers by MDPI demonstrated that multimodal machine learning frameworks can accurately infer hormone deviations from wearable biosensor data, achieving high accuracy when combining physiological and behavioral inputs.[5]

Translating that academic potential into a reliable consumer product, however, requires rigorous real-world validation. Inference-based systems face the inherent challenge of distinguishing between hormonal shifts and everyday physiological confounders, such as a poor night of sleep, an impending illness, or acute psychological stress.[6]

To address this, Clair has released early validation metrics from prototype testing on more than 40 women across 127 menstrual cycles, encompassing over 5,000 days of continuous wear. The company reports a 94.1 percent accuracy rate for cycle-phase classification, alongside an 87 percent sensitivity for detecting LH surges—a critical metric for predicting ovulation.[2]

Crucially, the company emphasizes that its models were trained on diverse physiologies, including data from women with polycystic ovary syndrome (PCOS) and anovulatory cycles. This deliberate inclusion aims to prevent the algorithms from overfitting to "textbook" hormonal patterns that fail to reflect reality for millions of users.[2]

To further cement its clinical credibility, Clair initiated an independent clinical trial through Stanford Medicine in May 2026. The peer-reviewed study is designed to establish how well the inference system performs across different ages, body mass indexes, and underlying health conditions, setting a higher bar than is typical for consumer wellness devices.[3]

Beyond accuracy, the architecture of the technology addresses a critical concern in modern women's health: data privacy. Clair's system is designed so that all hormone inference processing occurs locally on the user's smartphone. The sensitive health data never leaves the device or enters a cloud server, a feature the founders describe as non-negotiable in the current regulatory climate.[3][6]

Ultimately, the promise of continuous hormone monitoring extends far beyond fertility tracking. Hormones dictate metabolism, mental health, energy levels, and overall well-being. By providing women with a tangible, living record of their internal chemistry, the technology aims to validate their lived experiences, equipping them with the hard data needed to advocate for themselves in a healthcare system that has historically asked them to simply wait and see.[3][4]